ANKS6

Across TCGA pan-cancer cohorts, ANKS6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANKS6 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ANKS6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANKS6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

GBM, UCEC, and LSCC are the cancer types where ANKS6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.303	0.635	<.001	28	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.213	.006	26	view →
LSCC	OS	Tertile	II,III,IV	0.863	1.000	.028	5	view →
PDAC	DFS	Quartile	III,IV	0.385	1.000	.024	5	view →
LUAD	DFS	Tertile	All	0.764	0.466	.014	3	view →
CCRCC	DFS	Quartile	All	1.000	0.901	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANKS6–GBM (OS)

Open the GBM breakdown →